Shares of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT - Get Free Report) were up 1.7% on Thursday . The stock traded as high as GBX 1,489.20 ($20.01) and last traded at GBX 1,489.20 ($20.01). Approximately 150 shares traded hands during trading, a decline of 98% from the average daily volume of 7,246 shares. The stock had previously closed at GBX 1,463.80 ($19.67).
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Stock Performance
The company has a 50 day moving average of GBX 1,476.58 and a 200 day moving average of GBX 1,559.90. The stock has a market capitalization of £623.53 million and a price-to-earnings ratio of -1,381.83.
About First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
(
Get Free Report)
Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content.
Read More
Before you consider First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation wasn't on the list.
While First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access